Read more →
Project Manager, Global Public Affairs, Sanofi
Executive Director, European Biopharmaceutical Enterprises (EBE)
GaBI Journal is an independent and peer reviewed academic journal. GaBI Journal encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies.
More about GaBI Journal →
The extended stability studies of anticancer therapies published in 2024 cover 21 small molecules across 10 parenteral drug groups in oncology.
More about Special Report - Stability Studies →
Volume 13 / Year 2024 / Issue 3
Volume 13 / Year 2024 / Issue 2
Forthcoming Issue ▸
Recommend to a friend ▸
Request sample issue ▸
RSS feed ▸
Online First ▸
For Authors ▸
Call for Papers ▸
About GaBI Journal ▸
Subscribe ▸
Quick Links ▸
Sign up today for the weekly briefing on the latest developments in generic and biosimilar medicines!
Advertise ▸
Educational Workshops ▸
Educational Series ▸
Current Issue ▸
Fast Track ▸
Glossary of Key Terms / FAQs ▸
Guidance for Guest Authors ▸
Information for Authors ▸
Library Recommendation Form ▸
Submit a Manuscript ▸
Subscribe to a print or PDF copy of GaBI Journal ▸
Support GaBI !!! ▸
Sponsor a Supplement ▸
Reprints ▸
